Characteristics of patients from 1996 to 1999 by HAART exposure before NHL diagnosis
. | No prior HAART . | HAART pre-NHL . | χ2P value . |
---|---|---|---|
Cases NHL | 34 | 17 | |
Prior AIDS | 38% | 29% | .57 |
Stage I | 15% | 12% | .886-150 |
Stage II | 9% | 12% | |
Stage III | 6% | 12% | |
Stage IV | 70% | 65% | |
B symptoms | 91% | 71% | .063 |
Bone marrow involvement | 20% | 33% | .52 |
ECOG > 2 | 53% | 24% | .098 |
CD4 median (range) cells/mm3 | 107 (2-588) | 214 (8-636) | .0486-151 |
Mean age at NHL (y) | 42.6 (SD = 9.6) | 45.9 (SD = 7.6) | .226-152 |
. | No prior HAART . | HAART pre-NHL . | χ2P value . |
---|---|---|---|
Cases NHL | 34 | 17 | |
Prior AIDS | 38% | 29% | .57 |
Stage I | 15% | 12% | .886-150 |
Stage II | 9% | 12% | |
Stage III | 6% | 12% | |
Stage IV | 70% | 65% | |
B symptoms | 91% | 71% | .063 |
Bone marrow involvement | 20% | 33% | .52 |
ECOG > 2 | 53% | 24% | .098 |
CD4 median (range) cells/mm3 | 107 (2-588) | 214 (8-636) | .0486-151 |
Mean age at NHL (y) | 42.6 (SD = 9.6) | 45.9 (SD = 7.6) | .226-152 |